Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1330 • ACR Convergence 2025
Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Matthew Budoff¹ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens associate with cardioprotective benefits in the general population. Yet, dual pro- and anti-inflammatory effects were described in autoimmune states depending on concentration,…
Abstract Number: 1314 • ACR Convergence 2025
Protein-Specific Anti-Malondialdehyde-Acetaldehyde Antibodies and Cardiovascular Disease Outcomes in Rheumatoid Arthritis
Julia King¹, Michael Duryee¹, Punyasha Roul², Katherine Wysham³, Grant Cannon⁴, Gary Kunkel⁵, John Richards⁶, Isaac Smith⁷, Beth Wallace⁸, Gail Kerr⁹, Andreas Reimold¹⁰, Pascale Schwab¹¹, Daniel Anderson¹², Wenxian Zhou¹³, Joshua Baker¹⁴, Ted Mikuls¹, Bryant England¹ and Tate Johnson¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁷Duke University Hospital, Durham, NC, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹VA Portland and Oregon Health & Science University, Portland, OR, ^120587964, Durham, NC, ¹³University of Nebraska Medical Center, Bellevue, NE, ¹⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) remains the leading cause of death in rheumatoid arthritis (RA), driven primarily by atherosclerotic CVD (ASCVD) and heart failure (HF). Malondialdehyde-acetaldehyde…
Abstract Number: 1227 • ACR Convergence 2025
The Composition of Circulating Immune Cells is Associated with Nociplastic Pain in Patients with Rheumatoid Arthritis
Tyler Therron¹, Meghan Mayer², Cecilia Stumpf³, Gelis Galarcé Lugo⁴, Morgan Langereis⁵, Kathleen Aren⁶, Mary Carns⁵, Cally Mills⁵, Cheol Min Lee⁷, Vanessa Manada De Lobos², Carla Marie Cuda⁵, Yvonne Lee⁵ and Deborah Rachelle Winter⁸, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Chicago, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Zionsville, IN, ⁵Northwestern University, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Northwestern University, Skokie, IL
Background/Purpose: Over half of patients with RA report clinically meaningful pain, despite treatment with disease-modifying antirheumatic drugs (DMARDs). While joint inflammation is a known cause…
Abstract Number: 1055 • ACR Convergence 2025
The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
Antara Dattagupta¹, Colin Diffie² and Sana Cheema², ¹Washington University in St. Louis, St. Louis, MO, ²Washington University in St. Louis, St. Louis
Background/Purpose: High-cost biologic therapies are integral to the management of rheumatoid arthritis (RA), yet access to these agents may be influenced by insurance type, particularly…
Abstract Number: 0996 • ACR Convergence 2025
Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
Obinna Ubah, Euan Murray, Stella Priyanka, Julia Martinez Fraile, Andrew Porter, Robert Boyd and Caroline Barelle, Elasmogen Limited, Aberdeen, United Kingdom
Background/Purpose: Despite advances in therapies for chronic autoimmune diseases such as rheumatoid arthritis (RA), significant unmet needs persist, including therapeutic ceiling effects, adverse events, and…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
Abstract Number: 0814 • ACR Convergence 2025
Pain Patterns in a Multicenter Randomized Trial of Early RA – Link Between Initially Sustained Joint Inflammation and Subsequent Non-inflammatory Pain Outcomes
Annie Brink¹, Johan Karlsson Wallman², Jon T Einarsson¹, Meliha Kapetanovic¹, Elisabeth Mogard¹, Elisabet Lindqvist¹, Carmen Roseman¹, Kristina Lend³, Merete Hetland⁴, Mikkel Ostergaard⁵, Kim Horslev-Petersen⁶, Dan Nordstrom⁷, Tuulikki Sokka-isler⁸, Bjorn Gudbjornsson⁹, Gerður María Gröndal⁹, Marte Heiberg¹⁰, Espen Haavardsholm¹⁰, Michael Nurmohamed¹¹, Anna Rudin¹², Ronald van Vollenhoven¹³, Till Uhlig¹⁰, Jon Lampa¹⁴ and Tor Olofsson², ¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, ²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, ³Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam; Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁴Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup; Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark, ⁵Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, ⁶Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, ⁷Division of Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁸Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Juväskylä, Finland, ⁹Landspitali University Hospital; Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹¹Amsterdam Rheumatology and Immunology Center, Reade; Department of Rheumatology and Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹³Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁴Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Emerging data indicate an uncoupling between pain and inflammation during the RA disease course, and comorbid fibromyalgia – thought to stem from central pain…
Abstract Number: 0500 • ACR Convergence 2025
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Sama Hajizadeh¹, Tarun Sharma¹, Peri Newman², Julio Hernandez², Rayford June³, Erik Lehman², Nicole Wilson¹, Nancy Olsen⁴ and Sharon Banks⁵, ¹Allegheny Health Network, Pittsburgh, PA, ²Penn State Health/ Penn State College of Medicine, Hershey, PA, ³Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
Abstract Number: 0482 • ACR Convergence 2025
R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Christian Furlan Freguia¹, Janet Stephens¹, Sathya Janardhanan¹, Chuck Bourne¹, Kaitlyn Skeie¹, Hudson Lowe¹, David Pascual² and Gary Fanger¹, ¹Rise Therapeutics, Rockville, MD, ²University of Wyoming, Laramie, WY
Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
Abstract Number: 0466 • ACR Convergence 2025
Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Tulsi Joishy¹, Anastasiia Phothisane², Phicharmon Kulapatana² and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that is thought to originate at the mucosa. Despite the mucosa’s importance, few studies have examined…
Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Joel Kremer¹, Kevin Kane², George Reed³ and Michael Weinblatt⁴, ¹The Corrona Research Foundation, Delray Beach, FL, ²U of Mass Medical School, Worcester, MA, MA, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…
Abstract Number: 0432 • ACR Convergence 2025
Frequency and Characteristics of Ophthalmologic Involvement in Patients with Rheumatoid Arthritis
Javier Federico Flores Trejo¹, Joan Manuel Dapeña², Florencia Micaela Pascual³, Graciela Liliana Ghiglione¹, Juan Manuel Bande³, María Alejandra Medina³, José Angel Caracciolo³ and Silvia Beatriz Papasidero³, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Sanatorio Dr Julio Méndez, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ³Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that primarily affects synovial joints but may also involve extra-articular organs. Ocular involvement is one…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 0167 • ACR Convergence 2025
Geographic and Demographic Patterns of Rheumatoid Arthritis in the United States: Insights from GBD 2021
Punith Chirumamilla¹, Sameer Kumar Majety², Rithish Nimmagadda³, Ravi Medarametla⁴, Priya Sunkara⁵, Pranathi Bandarupalli⁶, Anjani Mahesh Kumar Cherukuri⁷ and Himaja Anne⁸, ¹Baptist Memorial Hospital North Mississippi, Oxford, MS, ²School of Medicine, Xiamen University, China, Kakinada, Andhra Pradesh, India, ³One Brooklyn Health, New York, NY, ⁴Mamata Medical College, Guntur, Andhra Pradesh, India, ⁵White River Health, Batesville, AZ, ⁶Mercy St Vincent Medical Center, Toledo, OH, ⁷Guntur Medical College, Guntur, Andhra Pradesh, India, ⁸Hind Institute of Medical Sciences, Sitapur, Uttar Pradesh, India
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune, systemic disease with a rising U.S. healthcare burden. Utilizing Global Burden of Disease (GBD) 2021 estimates, we analyzed…
Abstract Number: 0087 • ACR Convergence 2025
Integrative Metabolomic and Inflammatory Profiling in Rheumatoid Arthritis: Disease activity, therapeutic modulation, and underlying hepatic mechanisms
Laura muñoz-Barrera¹, Carlos Pérez Sánchez², Rafaela Ortega-Castro³, Sagrario Corrales¹, Tomás Cerdó¹, Ismael Sanchez-Pareja¹, Pilar Font⁴, Jerusalen Calvo Gutierrez⁵, M Carmen Abalos-Aguilera⁶, Desiree Ruiz-Vilchez⁷, Pedro Seguí-Azpilcueta⁸, Christian Merlo-Ruiz⁶, Jose Javier Pérez Venegas⁹, DOLORES RUIZ MONTESINOS¹⁰, Carmen Maria Romero Barco¹¹, Antonio Fernández-Nebro¹², Natalia Mena Vázquez¹³, FRANCISCO JAVIER GODOY NAVARRETE¹⁴, ALBA MARIA CABEZAS LUCENA¹⁵, MARIA ANGELES AGUIRRE ZAMORANO¹, Nuria Barbarroja¹⁶, Alejandro Escudero¹⁷ and Chary López pedrera¹⁸, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Sevilla, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, ⁸Radiology Service, Reina Sofia Hospital/Maimonides Institute for Research in Biomedicine of Cordoba/University of Cordoba, Spain, Córdoba, United Kingdom, ⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ¹⁰Virgen Macarena University Hospital, Sevilla, Spain, Cordoba, ¹¹Virgen de la Victoria Hospital Malaga, Spain, Malaga, Spain, ¹²Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ¹³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ¹⁴Jaen University Hospital, Spain, Jaen, Spain, ¹⁵Jaen University Hospital, Spain, Jaen, ¹⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Andalucia, Spain, ¹⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: Lipid metabolism plays a key role in immune cell plasticity, influencing activation, differentiation and function. Inflammation alters this metabolism, contributing to disease progression. Extensive…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].